In December 2021, the European Association for the Study of the Liver (EASL)–Lancet Commission on liver disease in Europe launched its first report, which highlighted an alarming increase in liver-related mortality in many European countries. The Commission proposed a roadmap for addressing the documented negative trends. However, quoting one of the accompanying Comment articles, “gaining consensus […]
Summary Background WHO has worked closely with member states to set baseline targets, monitor progress and gaps, and develop a strategy to achieve the elimination of viral hepatitis as a public health threat by 2030. This analysis aimed to use the latest data to assess global progress, identify gaps, and provide strategic support to countries […]
Summary Hepatitis D virus (HDV) is a small RNA virus that requires Hepatitis B Surface Antigen (HBsAg) for its envelope. Eight genotypes with more than 80 % sequence homology and many subgenotypes have been described. Worldwide prevalence of chronic hepatitis delta (CHD) is estimated at about 5 % of chronic hepatitis B cases, translating to […]
Accurate estimates of the prevalence of chronic hepatitis B virus (HBV) in the United States (US) are necessary for policy makers and community-based organisations to make informed decisions regarding the allocation of resources to work towards the elimination of HBV as a public health threat. The primary aim of this study was to quantify the […]
Despite global commitments to eliminate viral hepatitis by 2030, progress remains uneven. The Polaris Observatory tracks data from over 170 countries to evaluate hepatitis B (HBV) and C (HCV) elimination. While some nations have made significant strides—particularly in HCV treatment and HBV vaccination—few are on track to meet WHO’s full elimination targets. Barriers include complex […]
Hepatitis B (HBV) prevalence is very high in pregnant women in the Dolpa district of Nepal, a region characterised by a remote geographic landscape and low vaccination coverage. Using mathematical modelling, we evaluated the impact of third-trimester tenofovir disoproxil fumarate (TDF) prophylaxis on HBV burden and estimated the time required to achieve HBV elimination in […]
Increased funding for hepatitis C virus (HCV) research and care delivery is needed to support effective programs for vulnerable communities and meet the WHO 2030 targets for HCV elimination. Strategic collaborations among industry and nonindustry stakeholders can address this need. Establishing clear expectations, transparency, and investigator independence in these partnerships can enhance and accelerate HCV […]
Summary Background In countries with low baseline burdens of hepatitis B and C viruses (HBV, HCV), high levels of migration can impact the burden of viral hepatitis. The screening and treatment of migrants requires different methods and sensitivities than broad-based programs. We aimed to estimate the prevalence of HBV and HCV among migrants in EU-27 […]
Summary Metabolic dysfunction-associated steatotic liver disease (MASLD), the most rapidly increasing and prevalent cause of chronic liver disease, is associated with substantial healthcare costs. As disease burden and costs mount, pharmacologic therapy which halts MASLD fibrosis progression is coming to fruition. Modeling the impact on disease progression of a hypothetical pharmacologic therapy which halts MASLD […]
Summary The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infections by 2030. However, the HBV prevalence in Western countries, where the historical prevalence is low and highly impacted by immigration trends, remains uncertain making planning difficult. We aimed to develop a more accurate estimate of HBV prevalence and identify key […]
English 
Spanish 
French 
Chinese 
Russian 
Arabic